Investigating how IL-1 beta inhibition affects blood vessel inflammation in patients with specific genetic mutations.
Official title: Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis
Funded at Massachusetts General Hospital · NIH-11048029 · Data updated 2026-11-12
This study is looking at how inflammation affects heart health in people with a specific genetic change called TET2 clonal hematopoiesis, and it’s for those who have had heart problems before; participants will receive either a treatment to lower inflammation or a placebo, and we’ll see if this helps improve their heart health over a year.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $834,531 |
| NIH project number | 1R01HL173028-01A1 |
| Project ID | NIH-11048029 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with a history of cardiovascular disease and the TET2 clonal hematopoiesis mutation.
✕Less likely to help
Patients without a history of cardiovascular disease or those without the TET2 mutation may not benefit from this research.
What this research studies
This research focuses on understanding the role of inflammation in cardiovascular disease risk among individuals with a specific genetic mutation known as TET2 clonal hematopoiesis. The study will enroll participants with a history of heart issues and compare levels of vascular inflammation between those with and without this mutation. Participants will receive either a treatment that inhibits IL-1 beta or a placebo, and their vascular inflammation will be assessed using advanced imaging techniques over a 12-month period. The goal is to determine if the treatment can effectively reduce inflammation and improve heart health.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for reducing cardiovascular disease risk in patients with TET2 mutations.
How similar studies have gone: Previous research has shown promising results in targeting inflammation for cardiovascular disease, suggesting potential success for this approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Toribio, Mabel — Massachusetts General Hospital
- Study coordinator: Toribio, Mabel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.